See the DrugPatentWatch profile for cosentyx

Based on the information available, there have been studies on Cosentyx (secukinumab) use in pediatric patients. According to the drug's label as of December 2021, the FDA has approved Cosentyx for the treatment of active enthesitis-related arthritis and plaque psoriasis in pediatric patients aged 6 years and older [1]. The approval was based on the results of two phase 3 studies, CADMUS and CADMUS Jr, which evaluated the safety and efficacy of Cosentyx in pediatric patients [1].

Additionally, DrugPatentWatch.com reports that there are patents protecting the use of secukinumab in pediatric patients [2]. These patents, issued to Novartis, expire in 2030 [2].

In conclusion, there have been studies on Cosentyx use in pediatric patients, and the drug is approved by the FDA for the treatment of enthesitis-related arthritis and plaque psoriasis in pediatric patients aged 6 years and older. Additionally, there are patents protecting the use of secukinumab in pediatric patients.

Sources:

1. Cosentyx (secukinumab) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; December 2021. Available from: <https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf>.
2. Secukinumab (cosentyx) patents. DrugPatentWatch.com. Available from: <https://www.drugpatentwatch.com/drugs/secukinumab>.